Author: admin

GLD Acquires Seelos Therapeutics’ Assets, Strengthening GLD’s Growing Life Sciences Portfolio

GLD Announces Successful Closing of Seelos Assets; Includes Ketamine and Trehalose Programs Advancing into Phase 3 Clinical Trials

Los Angeles, CA, October 21, 2025 – GLD Partners, LP, with a growing footprint of investments in life sciences, healthcare, and biotech, today announced the successful acquisition of select assets from Seelos Therapeutics, Inc. through the Chapter 11 bankruptcy process.

Following its acquisition of Seelos’ senior secured debt, GLD served as the stalking horse bidder in the U.S. Bankruptcy Court in the Southern District of New York, and emerged as the successful acquirer through a Section 363 sale. The transaction includes Seelos’ late-stage ketamine and trehalose programs, both representing high-value opportunities in central nervous system (CNS) and rare disease therapeutics.

“Seelos’ ketamine and trehalose assets align with our strategy of acquiring scientifically validated, late-stage programs that were undercapitalized but hold transformative potential,” said Daniel Gordon, Managing Director of GLD Partners LP. “Merged into our existing biotech portfolio, these programs will benefit from GLD’s focused regulatory strategy and execution discipline, enabling efficient advancement toward patient impact.”

Clinical and Regulatory Pathway

While prior trials of both ketamine and trehalose faced operational and clinical challenges, the underlying science remains compelling. With enhancements to the intellectual property and a renewed focus on trial design and execution, GLD aims to advance both programs through late-stage development to address high unmet needs in CNS and rare disease therapeutics.

The ketamine program is positioned as a CNS therapy for major depressive disorder (MDD) and related neuropsychiatric conditions. GLD will initiate confirmatory Phase 3 pivotal trials aligned with FDA guidance, leveraging existing safety and efficacy data with enhanced study design and execution. 

The trehalose program is a disease-modifying therapy candidate for rare neurodegenerative and lysosomal storage disorders. GLD will progress trehalose into adaptive Phase 2/3 studies, supported by recent regulatory feedback and opportunities for orphan drug designation and expedited development.

Investor and Market Impact

Large market opportunities:

  • According to a Future Market Insights analysis, the global MDD therapeutics market is expected to exceed $15 billion annually by 2035, with ketamine-based treatments projected to drive significant growth.
  • Trehalose’s rare disease applications reside within a multibillion-dollar space for rare disease treatments, where orphan drug frameworks and premium per-patient pricing have supported high-value therapeutic opportunities.

    Capital-efficient acquisition: Through a capital-efficient acquisition, GLD acquired Seelos’ senior secured debt prior and assets at an attractive valuation with strong upside potential. 

    High-value synergy: These assets not only offer stand-alone value but also strengthen GLD’s existing portfolio of CNS and rare disease programs, enabling both clinical and commercial synergies.

    Pipeline acceleration: With enhanced trial design and GLD’s operational infrastructure, near-to mid-term value inflection points are expected from upcoming Phase 3 trials and regulatory milestones.

    “This transaction underscores our commitment to identifying underappreciated assets and executing the strategies needed to realize their full potential,” Gordon added. “We’re confident these programs can achieve meaningful clinical milestones and contribute lasting value across our life sciences portfolio.”

    About GLD Partners LP

    GLD Partners LP invests in private companies focused on healthcare and biotech innovation. The firm’s life sciences portfolio centers on advancing next-generation therapeutic platforms that have the potential to dramatically improve patient outcomes and medical breakthroughs. By combining deep scientific expertise with operational and financial leadership, GLD builds companies capable of delivering transformative medicines.

    For more information, https://www.gldlp.com/.

    GLD Launches New Biotech Company, Altagenics, to Accelerate Drug Discovery for Muscle-Wasting Diseases

    In collaboration with Heligenics GigaAssay™ platform, the companies will speed the development of new therapies in aging-related diseases.

    Los Angeles, CA, October 7, 2025 – GLD Partners, which invests in companies focused on healthcare and biotech innovation, today announced the launch of Altagenics, a new biotechnology company leveraging Heligenics’ proprietary GigaAssay™ platform to accelerate drug discovery. The collaboration will initially focus on discovering and developing first-in-class therapeutics for sarcopenia and cachexia, debilitating conditions characterized by age, drug, and disease-related muscle-wasting.

    This venture marks a significant milestone in GLD’s strategy to deploy transformational technologies that improve both the economics and the likelihood of success in drug discovery.

    The GigaAssay™ is a next-generation functional genomics technology capable of testing hundreds of thousands of protein variants in parallel, generating deep functional datasets that map genetic variation directly to biological impact. This scale of empirical testing provides unprecedented resolution of disease-relevant pathways and druggable targets. Unlike conventional discovery methods that rely on model-based inference or limited mutational scans, the GigaAssay™ delivers comprehensive, quantitative readouts of protein function and drug response, dramatically improving the precision and predictive power of early-stage discovery.

    “Altagenics exemplifies GLD’s approach that platform-driven discovery will define the next wave of biotech value creation,” said Daniel Gordon, Managing Director of GLD Partners LP. “By integrating the GigaAssay into a focused company structure, we can generate actionable datasets that rapidly translate into a differentiated pipeline for major unmet medical needs. This is a scalable model we expect to replicate across additional therapeutic areas.”

    Expanding the Frontier of Compound Discovery

    To unlock entirely new classes of therapeutics, Altagenics will apply the GigaAssay to systematically map protein function across pathways essential to muscle health and degeneration. This next-generation discovery approach is expected to yield thousands of novel, drug-like compounds with the potential to:

    • Treat sarcopenia and cachexia by targeting the molecular drivers of muscle wasting and age-related decline.
    • Promote muscle development and regeneration, creating entirely new therapeutic opportunities in sports medicine, rehabilitation, and metabolic health.
    • Establish a compound library of unprecedented breadth, serving as a cornerstone for precision drug design and future partnerships.

    By coupling massive-scale functional data with computational chemistry and AI-driven modeling, Altagenics aims to compress the timeline from hit discovery to candidate optimization, positioning the company as a leader in muscle-targeted therapeutics

    Strategic Rationale

    Altagenics combines a vast market opportunity, a differentiated discovery platform, and a scalable model for biotech innovation. The GigaAssay™ delivers a clear edge in discovery, identifying mechanisms and targets that traditional approaches often miss. Its data feed directly into structure-based design, AI-driven screening, and precision biomarker strategies, accelerating the path from discovery to candidate selection. This platform-first approach not only fuels Altagenics’ pipeline but also establishes a replicable model for future GLD-backed ventures advancing next-generation therapeutics.

    Dr. Martin Schiller, CEO of Heligenics, added: “The GigaAssay is the first functional readout of biology at industrial scale.  With GLD’s strategic and financial backing, Altagenics is uniquely positioned to translate this data advantage into a robust, de-risked therapeutic pipeline for sarcopenia, cachexia, and beyond.”

    About GLD Partners LP

    GLD Partners LP invests in private companies focused on healthcare and biotech innovation. The firm’s life sciences portfolio centers on advancing next-generation therapeutic platforms that have the potential to dramatically improve patient outcomes and medical breakthroughs. By combining deep scientific expertise with operational and financial leadership, GLD builds companies capable of delivering transformative medicines. For more information, https://www.gldlp.com/. 

    About Heligenics

    Heligenics is a pioneer in functional genomics. Its GigaAssay™ platform empowers researchers and partners to measure the functional consequences of nearly all possible protein variants, generating insights that accelerate drug discovery and precision medicine. For more information, https://www.heligenics.com/.

    About Altagenics

    Altagenics, founded by GLD Partners LP, is a biotechnology company advancing a new generation of first-in-class therapies. Leveraging Heligenics’ GigaAssay™, the company is accelerating the discovery of thousands of novel compounds to treat muscle wasting and promote muscle growth—addressing one of the most urgent and underserved needs in global healthcare. For more information, https://altagenics.com/.